A question of class: treatment options for patients with relapsed and/or refractory multiple myeloma
Multiple classes of agent with distinct mechanisms of action are now available for the treatment of patients with relapsed and/or refractory multiple myeloma (RRMM), including immunomodulatory agents, proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies. Additionally, several different drugs may be available within each agent class, each with their own specific efficacy and safety profile. This expansion of the treatment landscape has dramatically improved outcomes for patients.
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Gordon Cook, Sonja Zweegman, Mar ía-Victoria Mateos, Florence Suzan, Philippe Moreau Source Type: research